Search results
5 days ago · The Health Securer
1 day ago · The presence of the Philadelphia chromosome in ALL is associated with a poor prognosis, but the introduction of Bcr-Abl inhibitors has significantly improved outcomes for these patients as well. In combination with traditional chemotherapy, Bcr-Abl inhibitors have increased the remission rates and overall survival in Ph+ ALL patients.
4 days ago · It is a par@cular gene@c abnormality that is caused by corresponding transloca@on in chromosome 22 of cancerous cells. This chromosome carries a fusion gene that produces a hybrid protein. Chromosome 22 is also known as the Philadelphia chromosome. 4.
1 day ago · The Philadelphia chromosome, a hallmark of CML, leads to the creation of the Bcr-Abl fusion protein, which drives the malignant transformation of cells. Historically, the treatment of CML has been revolutionized by the development of TKIs such as imatinib (Gleevec).
2 days ago · Several earlier reports addressed the topic of resistance to InO (see figure).For example, patients with KMT2A-rearranged and Philadelphia chromosome-positive leukemias had lower response rates, which was associated with lower CD22 expression. 2 In pediatric samples, Pennesi et al described calicheamicin resistance as a mechanism of poor response, 3 but not CD22 expression, saturation, or ...
4 days ago · Involvement in Disease: Translocations can disrupt gene function and lead to disease, particularly if they involve important regulatory or coding regions. Example Disease: Chronic Myelogenous Leukemia (CML): Often caused by a translocation between chromosomes 9 and 22, creating the Philadelphia chromosome.
